Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to be safe in adults with latent TB infection (LTBI), but data are lacking for aerosol-delivered candidate TB vaccines in this population. We carried out a P...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Riste, M, Marshall, JL, Satti, I, Harris, SA, Wilkie, M, Lopez Ramon, R, Wright, D, Wittenberg, RE, Vermaak, S, Powell Doherty, R, Lawrie, A, Conlon, CP, Cosgrove, C, Gleeson, F, Lipman, M, Moss, P, Perrin, F, Dedicoat, M, Bettinson, H, McShane, H
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	MDPI 2021

Παρόμοια τεκμήρια

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <em>M.tb</em>-Infected Adults
ανά: Michael Riste, κ.ά.
Έκδοση: (2021-04-01)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
ανά: Thomas, Z, κ.ά.
Έκδοση: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
ανά: Tameris, M, κ.ά.
Έκδοση: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
ανά: Tameris, M, κ.ά.
Έκδοση: (2014)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
ανά: Mcshane, H
Έκδοση: (2008)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
ανά: Manjaly Thomas, Z, κ.ά.
Έκδοση: (2019)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
ανά: Rowland, R, κ.ά.
Έκδοση: (2012)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
ανά: Michele Tameris, κ.ά.
Έκδοση: (2014-01-01)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
ανά: Harris, S, κ.ά.
Έκδοση: (2011)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
ανά: Meyer, J, κ.ά.
Έκδοση: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
ανά: Meyer, J, κ.ά.
Έκδοση: (2013)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
ανά: Zita-Rose Manjaly Thomas, κ.ά.
Έκδοση: (2019-04-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
ανά: Anne Wajja, κ.ά.
Έκδοση: (2017-05-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
ανά: Wajja, A, κ.ά.
Έκδοση: (2017)

Phase I/II clinical trial of MVA85A in individuals with latent tuberculosis: The first subunit TB vaccine in clinical trial
ανά: Sander, C, κ.ά.
Έκδοση: (2005)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
ανά: Minassian, A, κ.ά.
Έκδοση: (2011)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
ανά: Harris, S, κ.ά.
Έκδοση: (2013)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
ανά: Odutola, A, κ.ά.
Έκδοση: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
ανά: Odutola, A, κ.ά.
Έκδοση: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
ανά: Dieye, T, κ.ά.
Έκδοση: (2013)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
ανά: Wilkie, M, κ.ά.
Έκδοση: (2019)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
ανά: Whelan, K, κ.ά.
Έκδοση: (2009)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
ανά: Pathan, A, κ.ά.
Έκδοση: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
ανά: Pathan, A, κ.ά.
Έκδοση: (2012)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
ανά: Owiafe, P, κ.ά.
Έκδοση: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
ανά: Tandakha N Dieye, κ.ά.
Έκδοση: (2013-01-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
ανά: Kathryn T. Whelan, κ.ά.
Έκδοση: (2011-01-01)

TB vaccine development: where are we and why is it so difficult?
ανά: Wilkie, M, κ.ά.
Έκδοση: (2014)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
ανά: Tandakha N. Dieye, κ.ά.
Έκδοση: (2013-01-01)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
ανά: Minhinnick, A, κ.ά.
Έκδοση: (2016)

Diagnosis of extrapulmonary TB: Experience with the Xpert MTB/Rif assay
ανά: C.N. Govind, κ.ά.
Έκδοση: (2014-04-01)

Evaluation of Xpert MTB/RIF assay for the diagnosis of paediatric TB
ανά: F. Ismail, κ.ά.
Έκδοση: (2014-04-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
Έκδοση: (2011-01-01)

Diagnostic performance of GeneXpert MTB/RIF in detecting MTB in smear-negative presumptive TB patients
ανά: Raksha Rimal, κ.ά.
Έκδοση: (2022-04-01)

Impact of introduction of Xpert MTB/RIF test on tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil.
ανά: Giovana Rodrigues Pereira, κ.ά.
Έκδοση: (2018-01-01)

Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB.
ανά: Neeraj Raizada, κ.ά.
Έκδοση: (2014-01-01)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
ανά: Mcshane, H, κ.ά.
Έκδοση: (2016)

TB or not TB?
ανά: Andrew Pirotte, κ.ά.
Έκδοση: (2024-04-01)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
ανά: Satti, I, κ.ά.
Έκδοση: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
ανά: Satti, I, κ.ά.
Έκδοση: (2014)